Search Results

Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) and Dianthus Therapeutics, Inc. (“Dianthus”), a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Magenta Therapeutics, Inc. announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan.

Magenta Therapeutics, a clinical-stage biotechnology company focused on improving stem cell transplantation, announced that it has completed a review of its business, including the status of its programs, resources, and capabilities.

Results from Magenta Medical’s Early Feasibility Study of the Elevate™ System, for the high-risk percutaneous coronary intervention (HR-PCI) indication, will be announced in an oral presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation in San Francisco. Elevate™ is the world’s smallest and most powerful percutaneous Left Ventricular Assist Device (pLVAD).

Magenta Medical, developer of the world’s smallest heart pump, announced the completion of enrollment to its FDA-approved Early Feasibility Study with the Elevate™ percutaneous Left Ventricular Assist Device for the high-risk percutaneous coronary intervention indication.

Magenta Therapeutics reported financial results for the third quarter ending September 30, 2022, and recent program highlights.

The US Early Feasibility Study of Magenta Medical’s Elevate™ System, designed to provide temporary mechanical circulatory support during high-risk percutaneous coronary intervention (HR-PCI) procedures, has successfully met its objectives.

Magenta Therapeutics is cutting about 84% of its workforce after a patient’s death halted a Phase I/II trial in acute myeloid leukemia.

Magenta Therapeutics today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors.

Magenta Medical, developer of the world’s smallest heart pump, announced a $55M financing round led by global healthcare investment manager OrbiMed, with participation from existing investors New Enterprise Associates, Pitango VC, and ALIVE - Israel HealthTech Fund.